Jasper Therapeutics to Present at Upcoming March Investor Conferences

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] Conference Participation - Jasper will participate in the TD Cowen 45th Annual Healthcare Conference from March 3-5, 2025, with a presentation scheduled for March 3 at 1:20 p.m. EST [2] - The company will also present at the Barclays 27th Annual Global Healthcare Conference from March 11-13, 2025 [2] - Additionally, Jasper will take part in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 12:30 p.m. EST [2] Product Development - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion via apoptosis, which addresses the inflammatory response in mast cell driven diseases [3] - The therapy has shown efficacy and safety in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU and CIndU [3]